Special Issue "Mechanisms of Tumor Latency and Its Alterations in Metastasis"
Deadline for manuscript submissions: 31 May 2018
Dr. Roger Gomis
Tumor cell dormancy remains one of the leading causes of cancer relapse after clinical treatment. Depending on their cellular microenvironment and genetic heterogeneity, disseminated tumor cells may proliferate or become quiescent. The mechanisms that govern tumor cell dormancy are not yet well understood and appear to involve cellular, angiogenic and immunological processes.
The aim of this Special Issue is to provide an updated view of the current status of research on metastasis and cancer dormancy, and their implications for better understanding cancer progression and treatment resistance.
Dr. Roger Gomis
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Tumor immunology and immunotherapy